Neurofilaments as biomarkers in multiple sclerosis

Multiple Sclerosis Journal

Volumn 18, Issue 5, 2012, Pages 552-556

  Teunissen, Charlotte E ^a   Khalil, Michael ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

biomarkers; disease progression; interlaboratory validation; Neurofilaments; treatment monitoring

Indexed keywords

ANTIBODY; NEUROFILAMENT PROTEIN;

CEREBROSPINAL FLUID; CLINICAL PRACTICE; DISABILITY; DISEASE COURSE; HUMAN; INFLAMMATION; MULTIPLE SCLEROSIS; NEUROFILAMENT; PREDICTIVE VALUE; PROGNOSIS; REVIEW; STANDARDIZATION;

EID: 84860448559     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512443092     Document Type: Review

References (39)

1. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain. 2006 ; 129: 606-616
2. Teunissen CE, Iacobaeus E, Khademi M, et al. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology. 2009 ; 72: 1322-1329
3. Deisenhammer F, Egg R, Giovannoni G, et al. EFNS guidelines on disease-specific CSF investigations. Eur J Neurol. 2009 ; 16: 760-770
4. Teunissen CE, Dijkstra CD, Polman CH. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol. 2005 ; 4: 32-41
5. Teunissen CE, Killestein J, Giovannoni G. Biomarker research in MS: addressing axonal damage and heterogeneity. Biomark Med. 2007 ; 1: 111-119
6. Dutta R, Trapp BD. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology. 2007 ; 68: S22 - S31
7. Filippi M, Bozzali M, Rovaris M, et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain. 2003 ; 126: 433-437
8. Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci. 2005 ; 233: 183-198
9. Fuchs E, Cleveland DW. A structural scaffolding of intermediate filaments in health and disease. Science. 1998 ; 279: 514-519
10. Gunnarsson M, Malmestrom C, Axelsson M, et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol. 2011 ; 69: 83-89
11. Petzold A, Mondria T, Kuhle J, et al. Evidence for acute neurotoxicity after chemotherapy. Ann Neurol. 2010 ; 68: 806-815
12. Norgren N, Sundstrom P, Svenningsson A, et al. Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology. 2004 ; 63: 1586-1590
13. Axelsson M, Malmestrom C, Nilsson S, et al. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis. J Neurol. 2011 ; 258: 882-888
14. Kuhle J, Leppert D, Petzold A, et al. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology. 2011 ; 76: 1206-1213
15. Lim ET, Sellebjerg F, Jensen CV, et al. Acute axonal damage predicts clinical outcome in patients with multiple sclerosis. Mult Scler. 2005 ; 11: 532-536
16. Brettschneider J, Petzold A, Junker A, et al. Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis. Mult Scler. 2006 ; 12: 143-148
17. Eikelenboom MJ, Petzold A, Lazeron RH, et al. Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy. Neurology. 2003 ; 60: 219-223
18. Kim S, Chang R, Teunissen C, et al. Neurofilament stoichiometry simulations during neurodegeneration suggest a remarkable self-sufficient and stable in vivo protein structure. J Neurol Sci. 2011 ; 307 (1-2). 132-8
19. Kuhle J, Regeniter A, Leppert D, et al. A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein. J Neuroimmunol. 2010 ; 220: 114-119
20. Norgren N, Rosengren L, Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res. 2003 ; 987: 25-31
21. Lu CH, Kalmar B, Malaspina A, et al. A method to solubilise protein aggregates for immunoassay quantification which overcomes the neurofilament 'hook' effect. J Neurosci Methods. 2011 ; 195: 143-150
22. Teunissen CE, Petzold A, Bennett JL, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology. 2009 ; 73: 1914-1922
23. Koel-Simmelink MJ, Teunissen CE, Behradkia P, et al. The neurofilament light chain is not stable in vitro. Ann Neurol. 2011 ; 69: 1065-1066
24. Huizinga R, Heijmans N, Schubert P, et al. Immunization with neurofilament light protein induces spastic paresis and axonal degeneration in Biozzi ABH mice. J Neuropathol Exp Neurol. 2007 ; 66: 295-304
25. Fabriek BO, Zwemmer JN, Teunissen CE, et al. In vivo detection of myelin proteins in cervical lymph nodes of MS patients using ultrasound-guided fine-needle aspiration cytology. J Neuroimmunol. 2005 ; 161: 190-194
26. Ehling R, Lutterotti A, Wanschitz J, et al. Increased frequencies of serum antibodies to neurofilament light in patients with primary chronic progressive multiple sclerosis. Mult Scler. 2004 ; 10: 601-606
27. Silber E, Semra YK, Gregson NA, et al. Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit. Neurology. 2002 ; 58: 1372-1381
28. Bartos A, Fialova L, Soukupova J, et al. Antibodies against light neurofilaments in multiple sclerosis patients. Acta Neurol Scand. 2007 ; 116: 100-107
29. Quintana FJ, Farez MF, Izquierdo G, et al. Antigen microarrays identify CNS-produced autoantibodies in RRMS. Neurology. 2012 ; 78: 532-539
30. Brettschneider J, Czerwoniak A, Senel M, et al. The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS). PLoS One. 2010 ; 5: e11986
31. Khademi M, Kockum I, Andersson ML, et al. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler. 2011 ; 17: 335-343
32. Sellebjerg F, Bornsen L, Khademi M, et al. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology. 2009 ; 73: 2003-2010
33. Gout O, Bouchareine A, Moulignier A, et al. Prognostic value of cerebrospinal fluid analysis at the time of a first demyelinating event. Mult Scler. 2011 ; 17: 164-172
34. Comabella M, Fernandez M, Martin R, et al. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain. 2010 ; 133: 1082-1093
35. Ottervald J, Franzen B, Nilsson K, et al. Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers. J Proteomics. 2010 ; 73 (6). 1117-32
36. Stoop MP, Dekker LJ, Titulaer MK, et al. Multiple sclerosis-related proteins identified in cerebrospinal fluid by advanced mass spectrometry. Proteomics. 2008 ; 8: 1576-1585
37. Sola P, Mandrioli J, Simone AM, et al. Primary progressive versus relapsing-onset multiple sclerosis: presence and prognostic value of cerebrospinal fluid oligoclonal IgM. Mult Scler. 2011 ; 17: 303-311
38. Thangarajh M, Gomez-Rial J, Hedstrom AK, et al. Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis. Mult Scler. 2008 ; 14: 1208-1213
39. Villar LM, Masjuan J, Gonzalez-Porque P, et al. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology. 2002 ; 59: 555-559